Intellia Therapeutics, Inc. Earnings Recaps
Q2 2026
Aug 9, 2026
Intellia shares jumped 8.8% following Q2 results, driven by compelling Phase III data on lonvo-z for hereditary angioedema and renewed momentum in the ATTR program, as clinical holds were lifted and enrollment resumed.
Key takeaways
- Lonvo-z Phase III HAELO trial demonstrated an 87% reduction in mean monthly attacks versus placebo over six months, with 62% of treated patients attack-free and therapy-free.
- All patients receiving lonvo-z showed attack rate reductions from baseline; benefits were consistent across demographics and prior therapy status.
- The rolling BLA submission for lonvo-z is underway, with FDA acceptance expected by year-end and a potential U.S. launch in the first half of next year.
- Nex-z Phase III trials for ATTR resumed in Q2 after resolving clinical holds, with investigator engagement and screening rates improving globally.
- Management highlighted the large unmet needs in the ATTR market and maintained confidence in combination therapy approaches despite recent negative trial results for a competitor’s silencer agent.
Q3 2025
Nov 7, 2025
Intellia Therapeutics faced significant challenges in Q3 2025, including a clinical hold on its nex-z program following serious safety concerns, while making substantial progress in its lonvo-z development for hereditary angioedema.
Key takeaways
- The FDA imposed a clinical hold on both the MAGNITUDE and MAGNITUDE-2 trials of nex-z due to safety issues, including increased liver enzyme levels in a patient who later passed away.
- Enrollment for the Phase III trial of lonvo-z was completed ahead of schedule, with top-line data expected by mid-2026 and a potential U.S. launch in early 2027.
- Intellia's cash position remains strong at $669.9 million, bolstered by a $115 million capital raise, extending its cash runway into mid-2027.
- Collaboration revenue climbed to $13.8 million, primarily due to cost reimbursements from Regeneron Pharmaceuticals, reflecting active partnerships.
- R&D expenses decreased to $94.7 million, driven by cost-cutting measures, highlighting the company's focus on managing operational expenditures amidst program uncertainties.